COMMITMENTS AND CONTINGENCIES (Details Narrative)		3 Months Ended		6 Months Ended
	May 31, 2023	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 AUD ($)	Dec. 31, 2023 USD ($)
Property, Plant and Equipment [Line Items]
Research and development expenses		$ 515,501	$ 2,395,589	$ 973,656	$ 4,249,981
Research and development expense tax credit receivable		261,058		261,058			$ 145,349
Future cash		3,502,551		3,502,551			$ 2,287,977
Reduction in force restructuring percentage	35.00%
Other Consulting and Vendor Agreements [Member]
Property, Plant and Equipment [Line Items]
Future cash		100,000		100,000
Avance Clinical [Member]
Property, Plant and Equipment [Line Items]
Contract cost		2,225,000		2,225,000		$ 3,400,000
Payment of contract cost		2,225,000		2,225,000
Prepaid assets		251,254		251,254
Research and development expenses		$ 154,354	$ 354,419	$ 244,390	$ 355,232